Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update.

Phillips EJ, Sukasem C, Whirl-Carrillo M, Müller DJ, Dunnenberger HM, Chantratita W, Goldspiel B, Chen YT, Carleton BC, George AL, Mushiroda T, Klein T, Gammal RS, Pirmohamed M
Clin Pharmacol Ther. 2018 103 (4): 574-581

PMID: 29392710 · PMCID: PMC5847474 · DOI:10.1002/cpt.1004

The variant allele HLA-B*15:02 is strongly associated with greater risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in patients treated with carbamazepine or oxcarbazepine. The variant allele HLA-A*31:01 is associated with greater risk of maculopapular exanthema, drug reaction with eosinophilia and systemic symptoms, and SJS/TEN in patients treated with carbamazepine. We summarize evidence from the published literature supporting these associations and provide recommendations for carbamazepine and oxcarbazepine use based on HLA genotypes.

© 2018 American Society for Clinical Pharmacology and Therapeutics.

MeSH Terms (7)

Anticonvulsants Carbamazepine Drug-Related Side Effects and Adverse Reactions HLA-B Antigens Humans Oxcarbazepine Pharmacogenetics

Connections (1)

This publication is referenced by other Labnodes entities: